Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
This randomized controlled, multi-center study will carry out to assess the efficacy of
 GB-0998 compared to plasmapheresis in the treatment of the generalized Myasthenia Gravis
 based on the changes in Quantitative Myasthenia Gravis score (QMG score) as primary endpoint,
 and in addition, to assess the safety of GB-0998
Inclusion Criteria:

 -  Patients diagnosed as generalized myasthenia gravis

 -  Patients who are not controlled by current therapy and need plasmapheresis therapy

 -  Patients who have the high-dose steroid therapy for over a month in past years, and
 also who take steroid or immunosuppressant on the day of consent

 -  Patients who had not any dose increase or new dosing of steroid or immunosuppressant
 within 4 weeks prior to enrollment

 Exclusion Criteria:

 -  Patients who received steroid pulse therapy, globulin therapy or plasmapheresis
 therapy within 12 weeks prior to enrollment

 -  Patients who had undergone thymectomy within 24 weeks prior to enrollment

 -  Patients with 3 points item in bulbar symptom of MG-ADL scale

 -  Patients with severe hepatic disorder, severe renal disorder or severe heat disorder

 -  Patients who have received treatment of malignant tumors

 -  Patients who have the anamnesis of shock or hypersensitivity to this drug

 -  Patients who have been diagnosed as hereditary fructose intolerance

 -  Patients who have the anamnesis of cerebral infarction or symptom of these diseases

 -  Patients who have been diagnosed as IgA deficiency in their past history

 -  Pregnant, lactating, and probably pregnant patients, and patients who want to become
 pregnant

 -  Patients who were administered other investigational drug within 12 weeks before
 consent